Edition:
United States

Johnson & Johnson (JNJ)

JNJ on New York Consolidated

122.92USD
24 Apr 2017
Change (% chg)

$1.16 (+0.95%)
Prev Close
$121.76
Open
$122.52
Day's High
$123.07
Day's Low
$122.15
Volume
3,314,045
Avg. Vol
6,778,149
52-wk High
$129.00
52-wk Low
$109.32

Latest Key Developments (Source: Significant Developments)

ChemDiv announces multi-year hit identification collaboration with Janssen
Tuesday, 31 Jan 2017 09:00am EST 

Johnson & Johnson - : ChemDiv-Entered into hit identification collaboration with Janssen to identify potent hit series for range of targets across multiple therapeutic areas .ChemDiv- Janssen is granted open-ended access to Chemdiv's discovery chemistry platform.  Full Article

Fitch affirms Johnson & Johnson's IDR at 'AAA'; outlook stable
Friday, 27 Jan 2017 03:42pm EST 

Fitch:Fitch affirms Johnson & Johnson's IDR at 'AAA'; outlook stable.  Full Article

DePuy Synthes receives FDA clearance for cement-augmented pedicle screw systems
Thursday, 26 Jan 2017 10:00am EST 

DePuy Synthes : DePuy Synthes receives FDA clearance for cement-augmented pedicle screw systems .Depuy synthes - Both fenestrated screw systems are anticipated to be available in United States in mid-2017.  Full Article

J&J has two-year agreement on stake in R&D company
Thursday, 26 Jan 2017 09:04am EST 

Johnson & Johnson : J&J says on investor call it has two year agreement not to sell on the open market any equity stake in actelion research and development unit . J&J says won't speculate on how long it will hold stake in research and development company (Reporting By Caroline Humer) ((caroline.humer@thomsonreuters.com;)).  Full Article

Actelion CEO hopes new R&D business to collaborate with J&J on products
Thursday, 26 Jan 2017 08:04am EST 

Actelion : Ceo says new research company to concentrate on development, focus on research for 1-2 years . Ceo says new company to have about 600 employees . Ceo says not sure of success of new company, but "very confident" . Ceo says new company will start with $1 billion in cash, 14 investigational products . Ceo says hopes to collaborate with j&j on products from new research and development company that he will head . Ceo says says will get potential royalties from ms drug, antibiotic from j&j . Ceo says did not speak with shareholder rudolf maag about transaction, "he has read about the deal this morning. I think he's going to like it." . Cfo says says source of cash in new company will be j&j equity stake, cash spun off from actelion demerger into new company . Ceo says nearly no overlap of companies to cause antitrust concerns .CEO says "With this structure it was not difficult. It's always emotional but it's not difficult. Because frankly it's a good solution for everybody.".  Full Article

Jupiter says J&J purchase of Actelion "very good outcome"
Thursday, 26 Jan 2017 06:00am EST 

: Jupiter Fund Manager Mike Buhl-nielsen: Johnson & Johnson purchase of actelion is "very good outcome", says can see "clear synergies for j&j" . Buhl-Nielsen holds Actelion shares Further company coverage: [JNJ.N] [ATLN.S] ((carolyn.cohn@thomsonreuters.com;)).  Full Article

Pacira Pharmaceuticals collaborates with Depuy Synthes to support promotion, education and training of exparel in orthopedics
Wednesday, 25 Jan 2017 07:30am EST 

Pacira Pharmaceuticals Inc : Pacira Pharmaceuticals announces collaboration with Depuy Synthes to support promotion, education and training of Exparel in orthopedics .Pacira Pharmaceuticals - initiation of agreement with Depuy Synthes sales to market and promote use of exparel for orthopedic procedures in U.S. market.  Full Article

J&J sees 2017 effective tax rate 19-20 percent
Tuesday, 24 Jan 2017 10:07am EST 

Johnson & Johnson : Johnson & Johnson ceo says no definitive timeline for review of diabetes care businesses . J&J CEO says planning expanded disclosures on drug pricing and research and development expenses . J&J says expects to launch 10 new products by 2019 with $1 billion sales potential . J&J CFO says plans to complete ongoing share repurchase program in 1H 2017 .J&J sees 2017 effective tax rate 19-20 percent.  Full Article

Ethicon Endo-Surgery announces acquisition of Megadyne Medical Products
Friday, 20 Jan 2017 08:30am EST 

Ethicon Endo-Surgery Inc: Ethicon Endo-Surgery says financial terms of transaction have not been disclosed .Ethicon announces acquisition of Megadyne Medical Products, Inc..  Full Article

Johnson & Johnson reports 7.4 pct stake in Merus NV as of Dec 31, 2016
Wednesday, 18 Jan 2017 05:59pm EST 

Johnson & Johnson :Johnson & Johnson reports 7.4 percent passive stake in Merus NV as of Dec 31, 2016 - SEC filing.  Full Article

More From Around the Web

J&J, Novartis and Takeda in talks for Brazil's Hypermarcas: sources

SAO PAULO Johnson & Johnson , Novartis AG and Takeda Pharmaceutical Co Ltd are in talks with the controlling bloc of Brazilian drugmaker Hypermarcas SA for a buyout, two people with knowledge of the matter said on Monday.